Sirexatamab

Sirexatamab (DKN-01) is a humanized IgG4 monoclonal antibody that can bind to and neutralize circulating DKK1. Sirexatamab exhibits antitumor activity in tumor models expressing DKK1[1].

Product Specifications

CAS Number

[2414962-49-3]

Product Name Alternative

DKN-01; LY-2812176

UNSPSC

12352203

Target

β-catenin

Type

Inhibitory Antibodies

Related Pathways

Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sirexatamab.html

Purity

99.84

Solubility

10 mM in DMSO

Smiles

[Sirexatamab]

Molecular Weight

(144 kDa)

References & Citations

[1]Klempner SJ, et al. Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers. Mol Cancer Ther. 2021 Nov;20 (11) :2240-2249.